Amneal Pharmaceuticals(AMRX)
$21.71+0.33 (+1.54%)
AMRX
Amneal Pharmaceuticals financials statements
$21.71
At close:+0.33 (+1.54%)
Want to see AMRX full AI Analyst Report?
Amneal Pharmaceuticals (AMRX) Ratios
635 Followers
Amneal Pharmaceuticals Ratios
AMRX's free cash flow for Q3 2026 was $60.70M. For the 2026 fiscal year, AMRX's free cash flow was decreased by $-39.58M and operating cash flow was $100.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.17 | 1.41 | 1.63 | 1.88 | 2.24 |
| Quick Ratio | 1.48 | 0.86 | 0.94 | 1.17 | 1.52 |
| Cash Ratio | 0.35 | 0.10 | 0.11 | 0.03 | 0.37 |
| Solvency Ratio | 0.08 | 0.03 | 0.04 | 0.03 | 0.07 |
| Operating Cash Flow Ratio | 0.39 | 0.26 | 0.41 | 0.09 | 0.36 |
| Short-Term Operating Cash Flow Coverage | 15.76 | 0.91 | 1.62 | 0.72 | 7.90 |
| Net Current Asset Value | $ -1.76B | $ -1.96B | $ -2.03B | $ -2.18B | $ -2.05B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.74 | 0.74 | 0.79 | 0.75 | 0.73 |
| Debt-to-Equity Ratio | -38.65 | -23.73 | 139.05 | 9.53 | 7.98 |
| Debt-to-Capital Ratio | 1.03 | 1.04 | 0.99 | 0.91 | 0.89 |
| Long-Term Debt-to-Capital Ratio | 1.03 | 1.05 | 0.99 | 0.90 | 0.88 |
| Financial Leverage Ratio | -51.96 | -32.04 | 175.55 | 12.73 | 10.93 |
| Debt Service Coverage Ratio | 2.26 | 0.72 | 1.16 | 1.75 | 2.34 |
| Interest Coverage Ratio | 1.75 | 0.96 | 0.97 | -0.60 | 1.12 |
| Debt to Market Cap | 0.67 | 1.02 | 2.49 | 9.06 | 3.85 |
| Interest Debt Per Share | 9.50 | 9.23 | 16.92 | 19.90 | 20.23 |
| Net Debt to EBITDA | 4.02 | 5.65 | 5.31 | 6.40 | 6.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 37.63% | 36.52% | 36.09% | 35.78% | 36.73% |
| EBIT Margin | 12.60% | 7.29% | 11.34% | 9.04% | 8.01% |
| EBITDA Margin | 20.00% | 15.74% | 20.92% | 19.90% | 19.16% |
| Operating Profit Margin | 14.02% | 8.92% | 8.54% | -4.29% | 7.29% |
| Pretax Profit Margin | 4.61% | -1.97% | -1.68% | -11.22% | 1.50% |
| Net Profit Margin | 2.39% | -4.18% | -3.51% | -5.88% | 0.51% |
| Continuous Operations Profit Margin | 4.24% | -2.64% | -2.04% | -11.52% | 0.96% |
| Net Income Per EBT | 51.76% | 212.47% | 208.57% | 52.39% | 33.87% |
| EBT Per EBIT | 32.90% | -22.06% | -19.70% | 261.38% | 20.54% |
| Return on Assets (ROA) | 1.96% | -3.34% | -2.42% | -3.42% | 0.27% |
| Return on Equity (ROE) | -101.78% | 106.97% | -424.61% | -43.56% | 2.95% |
| Return on Capital Employed (ROCE) | 15.13% | 10.51% | 7.78% | -3.12% | 4.68% |
| Return on Invested Capital (ROIC) | 13.80% | 9.19% | 7.16% | -3.01% | 2.97% |
| Return on Tangible Assets | 2.86% | -5.38% | -4.23% | -6.18% | 0.49% |
| Earnings Yield | 1.82% | -4.78% | -7.91% | -43.27% | 1.49% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.21 | 3.60 | 3.71 | 2.98 | 3.01 |
| Payables Turnover | 7.39 | 6.83 | 10.65 | 8.52 | 10.11 |
| Inventory Turnover | 3.11 | 2.90 | 2.63 | 2.68 | 2.71 |
| Fixed Asset Turnover | 5.49 | 5.34 | 4.35 | 3.75 | 3.28 |
| Asset Turnover | 0.82 | 0.80 | 0.69 | 0.58 | 0.53 |
| Working Capital Turnover Ratio | 4.06 | 5.65 | 4.02 | 2.95 | 2.44 |
| Cash Conversion Cycle | 181.81 | 173.91 | 202.92 | 215.87 | 219.84 |
| Days of Sales Outstanding | 113.64 | 101.34 | 98.46 | 122.39 | 121.12 |
| Days of Inventory Outstanding | 117.55 | 126.05 | 138.72 | 136.34 | 134.84 |
| Days of Payables Outstanding | 49.37 | 53.48 | 34.26 | 42.86 | 36.12 |
| Operating Cycle | 231.19 | 227.39 | 237.18 | 258.73 | 255.96 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.08 | 0.96 | 1.97 | 0.43 | 1.62 |
| Free Cash Flow Per Share | 0.86 | 0.71 | 1.58 | -0.17 | 1.30 |
| Dividend Paid and CapEx Coverage Ratio | 4.85 | 3.94 | 4.99 | 0.72 | 5.07 |
| Capital Expenditure Coverage Ratio | 4.85 | 3.94 | 4.99 | 0.72 | 5.07 |
| Operating Cash Flow Coverage Ratio | 0.12 | 0.11 | 0.13 | 0.02 | 0.08 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.11 | 0.14 | 0.03 | 0.12 |
| Free Cash Flow Yield | 6.84% | 8.99% | 26.02% | -8.49% | 27.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 54.78 | -20.94 | -12.65 | -2.31 | 67.14 |
| Price-to-Sales (P/S) Ratio | 1.31 | 0.88 | 0.44 | 0.14 | 0.34 |
| Price-to-Book (P/B) Ratio | -55.77 | -22.40 | 53.70 | 1.01 | 1.98 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 14.63 | 11.12 | 3.84 | -11.78 | 3.68 |
| Price-to-Operating Cash Flow Ratio | 11.61 | 8.29 | 3.07 | 4.61 | 2.95 |
| Price-to-Earnings Growth (PEG) Ratio | -0.34 | 1.00 | 0.29 | 0.00 | -0.76 |
| Enterprise Value Multiple | 10.56 | 11.21 | 7.43 | 7.09 | 8.33 |
| Enterprise Value | 6.37B | 4.93B | 3.72B | 3.12B | 3.34B |
| EV to EBITDA | 10.56 | 11.21 | 7.43 | 7.09 | 8.33 |
| EV to Sales | 2.11 | 1.76 | 1.55 | 1.41 | 1.60 |
| EV to Free Cash Flow | 23.61 | 22.40 | 13.46 | -122.36 | 17.22 |
| EV to Operating Cash Flow | 18.75 | 16.71 | 10.77 | 47.92 | 13.82 |
| Tangible Book Value Per Share | -3.68 | -4.45 | -8.16 | -9.84 | -9.35 |
| Shareholders’ Equity Per Share | -0.23 | -0.35 | 0.11 | 1.98 | 2.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | -0.34 | -0.21 | -0.03 | 0.36 |
| Revenue Per Share | 9.63 | 9.04 | 13.68 | 14.66 | 14.06 |
| Net Income Per Share | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 |
| Tax Burden | 0.52 | 2.12 | 2.09 | 0.52 | 0.34 |
| Interest Burden | 0.37 | -0.27 | -0.15 | -1.24 | 0.19 |
| Research & Development to Revenue | 0.06 | 0.07 | 0.08 | 0.09 | 0.10 |
| SG&A to Revenue | 0.17 | 0.17 | 0.17 | 0.17 | 0.00 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Income Quality | 4.72 | -3.99 | -7.09 | -0.26 | 22.76 |
Currency in USD
